ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 143 filers reported holding ASCENDIS PHARMA A/S in Q1 2019. The put-call ratio across all filers is 0.49 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7,381 | -99.9% | 82,699 | +50.1% | 0.01% | +57.1% |
| Q2 2020 | $8,147,000 | +41.6% | 55,082 | +7.8% | 0.01% | +16.7% |
| Q1 2020 | $5,752,000 | +38.5% | 51,078 | +71.2% | 0.01% | +100.0% |
| Q4 2019 | $4,152,000 | -42.2% | 29,843 | -60.0% | 0.00% | -50.0% |
| Q3 2019 | $7,185,000 | -65.3% | 74,599 | -58.5% | 0.01% | -66.7% |
| Q2 2019 | $20,704,000 | +98.1% | 179,799 | +102.5% | 0.02% | +80.0% |
| Q1 2019 | $10,452,000 | +252.0% | 88,799 | +111.9% | 0.01% | +233.3% |
| Q3 2018 | $2,969,000 | -29.2% | 41,900 | -33.6% | 0.00% | +50.0% |
| Q2 2018 | $4,192,000 | +865.9% | 63,140 | +850.9% | 0.00% | – |
| Q1 2018 | $434,000 | -30.1% | 6,640 | -57.2% | 0.00% | -100.0% |
| Q4 2017 | $621,000 | -48.8% | 15,500 | -53.7% | 0.00% | 0.0% |
| Q3 2017 | $1,214,000 | +71.7% | 33,500 | +31.5% | 0.00% | 0.0% |
| Q2 2017 | $707,000 | – | 25,470 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 11,225,357 | $1,001,863,112 | 18.92% |
| Q Global Advisors, LLC | 195,000 | $17,404 | 12.55% |
| Sofinnova Investments, Inc. | 754,032 | $67,297,356 | 4.41% |
| Avoro Capital Advisors LLC | 3,580,555 | $319,564,534 | 4.34% |
| Finepoint Capital LP | 139,772 | $12,474,651 | 4.32% |
| Spyglass Capital Management LLC | 657,853 | $58,713,380 | 4.24% |
| Saturn V Capital Management LP | 78,442 | $7,000,948 | 3.88% |
| DAFNA Capital Management LLC | 135,212 | $12,067,671 | 3.30% |
| ARS Investment Partners, LLC | 289,860 | $25,870,005 | 3.02% |
| Ghost Tree Capital, LLC | 100,000 | $8,925,000 | 2.95% |